[ad_1] Biocon Biologics has announced that the US Food and Drug Administration (FDA) has approved YESINTEK, a monoclonal antibody for the treatment of autoimmune conditions, including Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. YESINTEK works by targeting specific proteins that contribute to inflammation, offering a new treatment option for patients with these chronic […]
Headline
Tag: U.S. market
Back To Top